The time will come for marketing, but that time is not now. I disagree with your characterization of Dr. Missling. As a rule of thumb, if you don't believe management can execute then an investor should sell. Dr. Missling owns 8%+ of Anavex and isn't going anywhere.
They build relationships with the press who will publish news that has impact
I suggest you want to move on and invest in BIIB. They have top level marketing, sales leaders. Sadly, their science sucks but SOOO WHAT...they can market and sell the hell out of it.
BTW, BIOPHARMA top leaders who are also competent in the science do have to split(often contradictory) goals which they are responsible to balance. BIIB is a good example of this also. I am going to stick w/the solid-competent science team as long as they (get it) to balance the load on some time based scale. The biggest issue such a balanced team will have is TIME MANAGEMENT . The biggest conflicts they must manage are around (when is ENOUGH...ENOUGH and how do you know???
That is what we have here. The reality is (IMO) , in the CNS space, we have only just begun to scratch the surface of true baseline understanding. Stick around, you'll see. We do not yet know what we do not know. ....BUT, we do know enough to take the next required CNS AD CNS baby steps, IMO.
News 
Market Data 
Discover 
AI
